Results 271 to 280 of about 636,444 (331)

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Correction: Effectiveness of Novel Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Patel P, Patel SH, Siddegowda A, Potini BR, Miriyala V, Patel D, Singh N.   +6 more
europepmc   +1 more source

POTASSIUM REVERSION OF HYPOTHERMIC VENTRICULAR FIBRILLATION

, 1964
E. Converse Peirce
openalex   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Changes in physical activity before and after the diagnosis of dyslipidemia and the risk of atrial fibrillation: a population-based study in South Korea. [PDF]

Prev Med Rep
Kim HJ, Park SJ, Oh YH, Jeong S, Park SM.   +4 more
europepmc   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Comparative Readability Analysis of AI-Generated Versus Evidence-Based Educational Content on Atrial Fibrillation Management for Medical Professionals. [PDF]

Cureus
Konduru TS, Medapuram Belagu S, Momtaz A, Maghamifar J.   +3 more
europepmc   +1 more source

PHARMACOLOGICAL STUDIES ON FIBRILLATION VOLTAGES IN DENERVATED SKELETAL MUSCLE OF RABBIT

, 1962
Masao Morita, Motohiro Yasuhara, Jiro Sugimoto   +2 more
openalex   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

SGLT2 Inhibitor Might Prevent Atrial Fibrillation Related to Metabolic Syndrome via TNF-α Signaling Pathway: A Bioinformatic Study. [PDF]

J Arrhythm
Rizal A, Rohman MS, Prastya A, Fatchiyah F, Sujuti H, Rudianto A, Prayitnaningsih S.   +6 more
europepmc   +1 more source